What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

We recently published a list of 12 Most Profitable Growth Stocks To Invest In. In this article, we are going to take a look ...

(RTTNews) - AbbVie Inc. (ABBV), Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult patients with relapsed or refractory diffuse large ...

In August, EPKINLY was first listed, with specific reimbursement criteria, in Ontario and Quebec, and is now publicly funded in almost all remaining provinces, including Nova Scotia, British ...

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in ...

AbbVie Inc. ABBV reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus ...

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024HighlightsEuropean Commission (EC) granted ...

We are also seeing nice sequential revenue growth from Elahere and Epkinly, which are both demonstrating strong launch trajectories. Turning now to neuroscience, where total revenues were more ...

In August, EPKINLY was first listed, with specific reimbursement criteria, in Ontario and Quebec, and is now publicly funded in almost all remaining provinces, including Nova Scotia, British Columbia, ...